Martine Rothblatt, Chief Executive Officer of United Therapeutics Corp (UTHR), sold 1,982 shares of company stock in an open-market transaction on July 29, 2026. The shares were sold at a price of $524.47 each, yielding a total of $1,039,503. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission on July 30, one day after the transaction date.
That sale was one of eight open-market dispositions Rothblatt executed on July 29. Across all eight trades, she sold a combined 9,500 shares for proceeds of approximately $4.96 million. After the transactions, Rothblatt held 325,683 shares of United Therapeutics.
The July 29 activity continued a pattern of frequent selling by Rothblatt throughout the month. In July 2026 through July 29, she executed 80 open-market sales totaling $40.5 million, shedding 75,280 shares across eight trading dates: July 6, 7, 10, 15, 17, 21, 24, and 29. On July 15, she executed 16 separate open-market sales, the highest single-day transaction count during the month. On July 10, she executed 10 open-market sales. Each trading date involved sales across a range of prices, reflecting execution at various points during the session.
United Therapeutics, a biotechnology company in the pulmonary arterial hypertension space, carried a market capitalization of approximately $22.4 billion as of late July 2026.
Rothblatt has served as CEO of United Therapeutics since 1996, making her one of the longest-tenured chief executives in the biotechnology sector. Her Form 4 filings have consistently reported open-market sales during 2026, with selling activity concentrated in multi-trade clusters on individual trading days.
On the congressional side, two members of the U.S. House of Representatives have disclosed trades in United Therapeutics stock in recent years. Representative Michael T. McCaul, a Republican from Texas, executed multiple purchases and sales of UTHR shares between 2021 and 2025, with his most recent disclosures involving sales in October and November 2025. Representative Lisa McClain, a Republican from Michigan, reported purchases and sales of UTHR in 2025, including sales on October 30 and 31 of that year disclosed in November 2025. No member of Congress has filed a trade disclosure for United Therapeutics during 2026.